Susquehanna resumes coverage on Mindray Medical (NYSE: MR) with a Negative rating and $23 price target. This ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE